Mineralys Therapeutics (MLYS) Operating Income (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Operating Income data on file, last reported at -$45.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 2.01% year-over-year to -$45.3 million; the trailing twelve-month figure through Mar 2026 stood at -$171.5 million (up 14.88% YoY), and the FY2025 full-year result was -$170.6 million, up 11.33% from the prior year.
• Operating Income slipped to -$45.3 million in Q1 2026, from -$38.3 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$6.5 million in Q2 2022 to a low of -$60.1 million in Q3 2024.
• A 5-year average of -$30.9 million and a median of -$35.4 million in 2024 frame the typical range for Operating Income.
• Across the five-year window, Operating Income tumbled 253.94% in 2023 and surged 31.57% in 2025, its largest moves.
• Tracing MLYS's Operating Income over 5 years: stood at -$10.0 million in 2022, then slumped by 176.89% to -$27.7 million in 2023, then sank by 86.81% to -$51.8 million in 2024, then climbed by 26.05% to -$38.3 million in 2025, then decreased by 18.44% to -$45.3 million in 2026.
• Business Quant data shows MLYS's Operating Income at -$45.3 million in Q1 2026, -$38.3 million in Q4 2025, and -$41.1 million in Q3 2025.